Rapport Therapeutics (RAPP) Return on Capital Employed (2024 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Return on Capital Employed of 25.09% for Q1 2026, up 603.0% year-over-year from 3.57% in Q1 2025, and down 1.24% quarter-over-quarter from 24.78% in Q4 2025.
Rapport Therapeutics (RAPP) Return on Capital Employed (2024 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Return on Capital Employed for 3 consecutive years, with 25.09% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 603.0% year-over-year to 25.09%; the TTM figure through Mar 2026 stood at 25.09% (up 603.0% YoY), while the FY2025 annual figure was 31.7%, up 498.0% from the prior year.
- Return on Capital Employed retreated to 25.09% in Q1 2026 per RAPP's latest filing, from 24.78% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 22.42% in Q3 2024 and bottomed at 36.1% in Q2 2025.
- Historically, Return on Capital Employed has averaged 27.68% across 3 years, with a median of 26.43% in 2024.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 538 bps — and 2026, when it surged 603 bps.
- Rapport Therapeutics' Return on Capital Employed stood at 26.43% in 2024, then rose by 6 bps to 24.78% in 2025, then fell by 1 bps to 25.09% in 2026.
- Business Quant data shows RAPP's Return on Capital Employed at 25.09% in Q1 2026, 24.78% in Q4 2025, and 27.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | -34.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.12% |
| Mar 31, 2026 | -25.09% |
| Dec 31, 2025 | -24.78% |
| Sep 30, 2025 | -27.80% |
| Jun 30, 2025 | -36.10% |
| Mar 31, 2025 | -31.12% |
| Dec 31, 2024 | -26.43% |
| Sep 30, 2024 | -22.42% |